How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,113 results for

Headache in Pregnancy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Anesthetic approach to postdural puncture headache in the peripartum period: An Israeli national survey. (Abstract)

Anesthetic approach to postdural puncture headache in the peripartum period: An Israeli national survey. Accidental dural puncture frequency among pregnant women is about 1.5%, while approximately 60% of these women will suffer from post-dural puncture headache (PDPH) that may be debilitating.Following IRB approval, we conducted a national survey of the lead anesthesiologist in 23 labor and delivery rooms in Israel. Each survey inquired about medical center annual delivery volume, training

2018 Acta Anaesthesiologica Scandinavica

42. The Efficacy and Safety of Sphenopalatine Ganglion Pulsed Radiofrequency Treatment for Cluster Headache

radiofrequency Additional relevant MeSH terms: Layout table for MeSH terms Headache Cluster Headache Pain Neurologic Manifestations Signs and Symptoms Trigeminal Autonomic Cephalalgias Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases (...) Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle. Outcome Measures Go to Primary Outcome Measures : Duration of the cluster period [ Time Frame: Within 1 year (the cluster period is not over 3 months generally) ] The duration of the cluster period is defined as the total duration of the headache, including the pain attack time before and after treatment. Secondary Outcome Measures : The degree of pain during

2018 Clinical Trials

43. The Role of Inflammation and Vasodilatation in PACAP38-induced Headache Using MRI on Healthy Subjects

Aged 18-50 50-100 kg Exclusion Criteria: Tension type headache more than 5 dag /month Other primary headaches Daily medication except contraceptives Drug taken within 4 times the half-life for the specific drug except contraceptives Pregnant or lactating women Exposure to radiation within the last year Headache within the last 24 hours before start of trial Hypertension Hypotension Respiratory or cardiac disease Primary relatives with current or previous migraine Contacts and Locations Go (...) Product: No Additional relevant MeSH terms: Layout table for MeSH terms Inflammation Headache Pathologic Processes Pain Neurologic Manifestations Signs and Symptoms Ketorolac Ketorolac Tromethamine Sumatriptan Pituitary Adenylate Cyclase-Activating Polypeptide Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme

2018 Clinical Trials

44. Continuous Positive Airway Pressure as a Potential New Treatment for Cluster Headache

3.1.2. is able to separate cluster headache attacks from other types of headache. agrees to maintain current preventive headache and sleep medication regimens (no change in type, frequency, or dose) during the whole study period. Signed informed consent. Exclusion Criteria: disorders with contraindications for use of continuous positive airway pressure (e.g. unable to remove the ventilation mask due to a movement disorders). Nightly cluster headache attacks Pregnancy or planned pregnancy having had (...) a change in type, dosage or dose frequency of preventive headache or sleep medications < 1 months prior to inclusion. Severe depression or other psychiatric disorder that may interfere with the treatment. Abuse of alcohol or illicit drugs. Other severe chronic pain conditions Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please

2018 Clinical Trials

45. Neuroinflammatory Response and Headache Control in Patients After Subarachnoid Hemorrhage

First Posted : July 27, 2018 Last Update Posted : July 27, 2018 See Sponsor: Maine Medical Center Information provided by (Responsible Party): Elizabeth Glisic, Maine Medical Center Study Details Study Description Go to Brief Summary: The purpose of this study is to determine the relationship between the Neuroinflammatory response and headache pain after subarachnoid hemorrhage. Condition or disease Subarachnoid Hemorrhage, Aneurysmal Headache Subarachnoid Hemorrhage Detailed Description: Persistent (...) to determine the magnitude and dynamics of their neuroinflammatory response. In addition, the investigators will collect and analyze observational data about the success of medications to treat headache, with a specific focus on the anti-inflammatory agent dexamethasone, in managing acute headache pain and preventing the development of persistent headaches in patients after SAH. Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 40 participants

2018 Clinical Trials

46. Reproductive Headache? Investigating Acetaminophen as a Potential Endocrine Disruptor Full Text available with Trip Pro

Animals Endocrine Disruptors therapeutic use Female Headache drug therapy Humans Male Pregnancy Reproduction drug effects 2017 07 06 2017 07 06 2018 3 13 6 0 2018 3 13 6 0 2019 2 5 6 0 epublish 29529598 10.1289/EHP2478 EHP2478 PMC6071750 Paediatr Perinat Epidemiol. 2012 Sep;26(5):456-67 22882790 Schizophr Res. 2011 Mar;126(1-3):220-5 21146371 Int J Epidemiol. 2016 Dec 1;45(6):1987-1996 27353198 Hum Reprod. 2016 Sep;31(9):2119-27 27412248 Toxicol Sci. 2016 Mar;150(1):178-89 26732887 Arch Dis Child (...) Reproductive Headache? Investigating Acetaminophen as a Potential Endocrine Disruptor 29529598 2019 02 04 2019 02 15 1552-9924 126 3 2018 03 09 Environmental health perspectives Environ. Health Perspect. Reproductive Headache? Investigating Acetaminophen as a Potential Endocrine Disruptor. 032001 10.1289/EHP2478 Konkel Lindsey L eng Journal Article 2018 03 09 United States Environ Health Perspect 0330411 0091-6765 0 Endocrine Disruptors 362O9ITL9D Acetaminophen IM Acetaminophen therapeutic use

2018 Environmental health perspectives

47. SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture

: University Hospital, Toulouse Information provided by (Responsible Party): University Hospital, Toulouse Study Details Study Description Go to Brief Summary: Headache control is one of the major challenges in patients who suffered an acute aneurysmal subarachnoid hemorrhage (aSAH). Headache affects 90% of the patient and is resistant to the major pain medication. It results from the increased intracranial pressure and the inflammation caused by the accumulation of arterial blood in the subarachnoid space (...) Aneurysmal Subarachnoid Hemorrhage Headache Procedure: Lumbar puncture Not Applicable Detailed Description: After aneurysmal subarachnoid hemorrhage (aSAH) almost 90 % of patients experience a severe headache during their hospital stay. Pain control often requires high doses of opioid drugs and sedation that remain only partially efficacious. In addition, there is to the investigator's knowledge currently no recommendation or consensus on aSAH related headache management. aSAH related headache results

2018 Clinical Trials

48. Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children

Recruitment Status : Recruiting First Posted : February 27, 2018 Last Update Posted : July 30, 2018 See Sponsor: Boston Children’s Hospital Information provided by (Responsible Party): Alyssa Lebel, MD, Boston Children’s Hospital Study Details Study Description Go to Brief Summary: New daily persistent headache (NDPH) is a primary headache disorder characterized by the daily and unremitting headache pain patients experience with a distinct onset. Despite the known significant impairment associated (...) or disease Intervention/treatment Phase New Daily Persistent Headache (NDPH) Drug: Naltrexone HCl (Bulk) Powder Phase 1 Phase 2 Detailed Description: The purpose of this study is to investigate low-dose naltrexone for the treatment of new daily persistent headache (NDPH) in adolescents ages 10-17. New daily persistent headache (NDPH) is a primary headache disorder characterized by continuous pain experienced for at least 3 months from distinct onset. Patients with NDPH have compromised academic

2018 Clinical Trials

49. Headaches Through a Woman's Life. (Abstract)

Headaches Through a Woman's Life. Headaches affect women across their life span, with menses, pregnancy, and menopause being times that pose unique challenges in diagnosis and treatment. The correct diagnosis and treatment of headache can prevent unnecessary interventions, the worsening of chronic headache disorders, and complications of secondary headaches.The objective of this article is to educate women's health care providers about the diagnosis, differential diagnosis, and treatment (...) of headache during menses, pregnancy, the puerperium, and menopause to improve the quality of care for women with chronic and acute headache.Current articles were reviewed addressing headache during menses, pregnancy, the postpartum period, and menopause. Articles with the highest level of evidence were compiled in this article to provide a summary of recommendations.Multiple diagnostic and therapeutic options for chronic and acute headache are available for women regardless of their stage in life

2018 Obstetrical & Gynecological Survey

50. Comparison of Effects of Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches

and older (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Chronic migraine diagnosis according to International Classification of Headache-2 Disorders (ICHD) w/o pregnancy or breastfeeding. w/o acute or chronic psychiatric disorders. w/o nephrolithiasis. w/o medication of anticoagulant and antiaggregant. w/o allergy to topiramate or bupivacaine. w/o prophylaxis within the last three months with any of; propranolol, nebivolol (...) Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Mustafa Ceylan, Ataturk University: Medication overuse headache; Greater occipital nerve block; supratrochlear nerve block; topiramate. Additional relevant MeSH terms: Layout table for MeSH terms Headache Headache Disorders, Secondary Pain Neurologic Manifestations Signs and Symptoms Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Topiramate Anticonvulsants Hypoglycemic

2018 Clinical Trials

51. Hypertension in pregnancy: diagnosis and management

Reducing the risk of hypertensive disorders in pregnancy Symptoms of pre-eclampsia Symptoms of pre-eclampsia 1.1.1 Advise pregnant women to see a healthcare professional immediately if they experience symptoms of pre-eclampsia. Symptoms include: severe headache problems with vision, such as blurring or flashing before the eyes severe pain just below the ribs vomiting sudden swelling of the face, hands or feet. See the NICE guideline on antenatal care for advice on risk factors and symptoms of pre (...) are in a critical care setting if birth is planned within 24 hours. [2010] [2010] 1.8.3 Consider the need for magnesium sulfate treatment, if 1 or more of the following features of severe pre-eclampsia is present: ongoing or recurring severe headaches visual scotomata nausea or vomiting epigastric pain oliguria and severe hypertension Hypertension in pregnancy: diagnosis and management (NG133) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

52. Ectopic pregnancy and miscarriage: diagnosis and initial management

and miscarriage: diagnosis and initial management (NG126) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 33This guideline replaces CG154. This guideline is the basis of QS69. Ov Overview erview This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how (...) for an ultrasound scan Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5 of 33what to expect during the course of her care (including expectant management), such as the potential length and extent of pain and/or bleeding, and possible side effects. This information should be tailored to the care she receives information about post-operative care

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

53. Headache in Pregnancy: An Approach to Emergency Department Evaluation and Management Full Text available with Trip Pro

Headache in Pregnancy: An Approach to Emergency Department Evaluation and Management Headache is a common presenting complaint in the emergency department. The differential diagnosis is broad and includes benign primary causes as well as ominous secondary causes. The diagnosis and management of headache in the pregnant patient presents several challenges. There are important unique considerations regarding the differential diagnosis, imaging options, and medical management. Physiologic changes (...) induced by pregnancy increase the risk of cerebral venous thrombosis, dissection, and pituitary apoplexy. Preeclampsia, a serious condition unique to pregnancy, must also be considered. A high index of suspicion for carbon monoxide toxicity should be maintained. Primary headaches should be a diagnosis of exclusion. When advanced imaging is indicated, magnetic resonance imaging (MRI) should be used, if available, to reduce radiation exposure. Contrast agents should be avoided unless absolutely

2015 Western Journal of Emergency Medicine

54. The Role of Headache in the Classification and Management of Hypertensive Disorders in Pregnancy. (Abstract)

The Role of Headache in the Classification and Management of Hypertensive Disorders in Pregnancy. Hypertensive disorders of pregnancy remain among the leading causes of maternal morbidity and mortality. The onset of headaches in patients with hypertensive disorders of pregnancy has been considered as a premonitory symptom for eclampsia and other adverse maternal outcomes. Headaches are very common symptoms during pregnancy and the postpartum period with a reported incidence of 39%; however (...) , headache is absent in 30-50% of women before the onset of eclampsia and is a poor predictor of eclampsia and adverse maternal outcomes. If included in the definition of cerebral or visual disturbances, headache may be considered a symptom of preeclampsia, a diagnostic feature of preeclampsia with severe features, a premonitory symptom of eclampsia, and an indication for delivery. Inclusion of this nonspecific symptom in the diagnosis and management of hypertensive disorders of pregnancy in the absence

2015 Obstetrics and Gynecology

55. Towards integrated antenatal care for low-risk pregnancy

of the pregnancy What you need to know before reading this section This section is based on data coming from various sources: The Planning Unit for Healthcare Professions Workforce within the Federal Public Service Public Health provided statistics related to healthcare professionals on 31 December 2017 (head counts and full- time equivalents [FTE]); The care consumption is described using AIM/IMA administrative data related to (insured) pregnant women’s characteristics (age, residence, insurance coverage (...) engaged in non-clinical interventions 28 3.2.4 How to improve BPPE: Literature review and stakeholders consultation 28 3.3 ICT INNOVATIONS FOR INFORMATION EXCHANGE 31 4 LEGAL FRAMEWORK OF ANC AND PROTECTIVE MEASURES FOR PREGNANT WOMEN IN BELGIUM 33 4.1 LEGAL FRAMEWORK OF ANC IN BELGIUM 33 4.2 PROTECTIVE MEASURES FOR (VULNERABLE) PREGNANT WOMEN 34 2 Towards integrated antenatal care for low-risk pregnancy KCE Report 326 5 PROVISION AND UPTAKE OF ROUTINE ANC: PARENTS’ AND HEALTHCARE PROFESSIONALS

2020 Belgian Health Care Knowledge Centre

56. Association of Migraine Headaches With Suicidal Ideation Among Pregnant Women in Lima, Peru. Full Text available with Trip Pro

with increased odds of suicidal ideation in pregnant women even when controlling for depression. These findings support the consideration of screening women with comorbid migraine and depression for suicidal behavior during pregnancy.© 2016 American Headache Society. (...) Association of Migraine Headaches With Suicidal Ideation Among Pregnant Women in Lima, Peru. Suicide is a leading cause of maternal death globally, and suicide prevalence rates have been shown to be increased in those with migraine. No previous study has examined the association between migraine and suicidal ideation during pregnancy.To examine the association between migraine and suicidal ideation among a cohort of pregnant women.A cross-sectional study was conducted among 3372 pregnant women

2016 Headache

57. A Pregnant Woman with Headache

A Pregnant Woman with Headache Rotation Prep | NEJM Resident 360 Social Login Email Login Log in via Email Create Your Account We will not share your email with anyone. Password must be at least 8 characters. Show or Hide the password you are typing. Request to Join has invited you to join this group Your browser does not support video tags Welcome! NEJM Resident 360 helps you prepare for your next rotation quickly and efficiently, provides support for coping with the pressures of resident life

2015 Now@NEJM

58. The Effect of Sumatriptan and Placebo on CGRP Induced Headache

. Exclusion Criteria: Healthy: Any type of headache (except episodic tension-type headache < 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily medication (except oral contraceptives). Migraine patients: Any other type of headache then migraine without aura (except episodic tension-type headache < 1 day per week) Serious somatic or psychiatric disease Pregnancy Intake of daily medication (except oral contraceptives) Triptan non-responders Contacts and Locations Go (...) Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Headache Pain Neurologic Manifestations Signs and Symptoms Sumatriptan Calcitonin Katacalcin Calcitonin Gene-Related Peptide Vasoconstrictor Agents Serotonin 5-HT1 Receptor Agonists Serotonin Receptor Agonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Calcium-Regulating Hormones and Agents Bone Density

2017 Clinical Trials

59. Capsaicin in Treatment of Rhinogenic Headache

Medical center complaining of headaches/ facial pain and pressure Diagnosis of a primary rhinogenic headache disorder by the senior authors. Exclusion Criteria: Exclusion criteria include: pregnancy, age less than 19, active history of smoking, presence of confirmed sinonasal disease, fibromyalgia, poorly controlled chronic health problems, allergies to chili peppers or any ingredient in the nasal spray, or confirmed Temporal Mandibular Joint (TMJ) arthralgia as the etiology of primary headache (...) to receive two bottles of either eucalyptol spray (placebo) or sinus buster (capsaicin) spray and are blinded to the content of the spray bottle. They are instructed to use the nasal spray one to two times daily. Subjects are permitted to continue to take headache medication as needed, but it must be recorded in their symptom journal. The journal is completed daily, and includes medication use, a headache pain score, and side effect log. Additionally, subjects fill out SinoNasal Outcome test (SNOT)22

2017 Clinical Trials

60. Psilocybin for the Treatment of Migraine Headache

test session ] Measured in days Change in migraine attack frequency [ Time Frame: From two weeks before first session to two weeks after second session using a headache diary ] Average number (number per week) Change in migraine attack duration [ Time Frame: From two weeks before first session to two weeks after second session using a headache diary ] Average duration (measured in hours) Change in pain intensity of migraine attacks [ Time Frame: From two weeks before first session to two weeks (...) after second session using a headache diary ] Average pain intensity (4-tiered pain score; 1=none, 2=mild, 3=moderate, 4=severe) Change in intensity of nausea/vomiting during migraine attacks [ Time Frame: From two weeks before first session to two weeks after second session using a headache diary ] Average intensity (4-tiered pain score; 1=none, 2=mild, 3=moderate, 4=severe) Change in intensity of photophobia [ Time Frame: From two weeks before first session to two weeks after second session using

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>